MALVERN, Pa., July 18, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the first patient has been dosed in its Phase 2/3 GARDian3 clinical trial for...Read more
PRINCETON, N.J. / Jul 18, 2025 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 INDEPENDENCE trial evaluating Reblozyl® (luspatercept-aamt) with concomitant janus kinase inhibitor (JAKi) therapy in adult patients with myelofibrosis-associated anemia...Read more
PITTSBURGH, July 18, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that a randomized, double-masked, vehicle-controlled, Phase 3 study to evaluate the efficacy and safety of pimecrolimus 0.3% (MR-139) ophthalmic ointment in...Read more
SOUTH SAN FRANCISCO, Calif. / Jul 18, 2025 / Business Wire / Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for Genentech’s supplemental Biologics License Application (sBLA)...Read more
New Drug Application supported by results from the Phase 2b SunRISe-1 study RARITAN, N.J., July 17, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) granted Priority Review to the New Drug Application (NDA) filed for...Read more
The Breakthrough Therapy Designation (BTD) was granted based on the highly compelling results from the Phase 2 EMBOLD trial in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) The EMBOLD cohort 2 pivotal trial is on track for topline results in H1 2026 with NDA filing to...Read more
Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Eli Lilly | 11.43 1.50 | $772.94 |
| CRISPR Therapeutics | 10.11 18.35 | $65.20 |
| Veeva Systems | 5.83 2.11 | $282.29 |
| Bolt Biotherapeutics | 4.97 887.50 | $5.53 |
| Cyclacel Pharmaceuticals | 4.57 55.53 | $12.80 |
| Cidara Therapeutics | 3.77 6.71 | $59.96 |
| Mesoblast | 3.33 26.99 | $15.67 |
| Abbott | 3.16 2.62 | $123.67 |
| Nutex Health | 3.03 2.74 | $113.81 |
| Intuitive | 2.46 0.48 | $518.62 |
| Tarsus Pharmaceuticals | 1.85 4.47 | $43.25 |
| Merus | 1.82 2.96 | $63.26 |
| Ligand Pharmaceuticals | 1.53 1.11 | $139.10 |
| ResMed | 1.50 0.58 | $257.92 |
| MEI Pharma | 1.45 32.22 | $5.95 |
| RAPT Therapeutics | 1.45 14.17 | $11.68 |
| PureTech Health | 1.17 6.32 | $19.67 |
| Eton Pharmaceuticals | 1.09 7.82 | $15.02 |
| Company | Volume | Last Trade |
|---|---|---|
| Incannex Healthcare | 462,409,334 | $0.65 |
| Telomir Pharmaceuticals | 135,310,719 | $2.28 |
| Healthcare Triangle | 114,250,306 | $0.02 |
| Sarepta Therapeutics | 75,535,509 | $14.06 |
| NuCana | 64,589,035 | $0.05 |
| Oscar Health | 64,410,901 | $13.41 |
| Recursion | 53,032,415 | $5.85 |
| MEI Pharma | 41,046,545 | $5.95 |
| Pfizer | 32,867,328 | $24.47 |
| Centene | 22,281,880 | $27.90 |
| Cyclacel Pharmaceuticals | 22,092,607 | $12.80 |
| Windtree Therapeutics | 18,973,361 | $1.19 |
| Abbott | 17,371,092 | $123.67 |
| Senseonics | 15,619,626 | $0.58 |
| Iovance Biotherapeutics | 14,668,113 | $2.23 |
| UnitedHealth | 14,195,974 | $282.58 |
| Atai Life Sciences | 14,119,465 | $3.23 |
| Teva Pharmaceutical | 11,847,977 | $16.06 |
| AbCellera Biologics | 11,515,121 | $4.51 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. The company's lead cell therapy asset is NXC-201 in multiple myeloma...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including a small-molecule GLP-1 receptor...
CLICK TO LEARN MORE
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking’s research and development activities leverage...
CLICK TO LEARN MORE
